Galmed Pharmaceuticals Holds Annual Shareholder Meeting

Ticker: GLMD · Form: 6-K · Filed: Oct 29, 2025 · CIK: 1595353

Galmed Pharmaceuticals LTD. 6-K Filing Summary
FieldDetail
CompanyGalmed Pharmaceuticals LTD. (GLMD)
Form Type6-K
Filed DateOct 29, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: shareholder-meeting, corporate-governance

TL;DR

Galmed Pharma held its shareholder meeting on Oct 29, voted on proxy items.

AI Summary

On October 29, 2025, Galmed Pharmaceuticals Ltd. held its Annual General Meeting of Shareholders. Shareholders voted on proposals previously outlined in the company's proxy statement filed on September 19, 2025. The specific outcomes of these votes were not detailed in this filing.

Why It Matters

This filing confirms the holding of the annual shareholder meeting, a routine corporate governance event where shareholders exercise their voting rights on company matters.

Risk Assessment

Risk Level: low — This filing is a routine update on a shareholder meeting and does not contain new financial or operational information that would typically increase risk.

Key Players & Entities

FAQ

What was the purpose of the Form 6-K filing?

The Form 6-K filing was to report on the Annual General Meeting of Shareholders held by Galmed Pharmaceuticals Ltd. on October 29, 2025.

When was the Annual General Meeting of Shareholders held?

The Annual General Meeting of Shareholders was held on October 29, 2025.

What proposals were voted on at the meeting?

Shareholders voted on all proposals described in the proxy statement for the meeting, which was filed on September 19, 2025.

Where is Galmed Pharmaceuticals Ltd. located?

Galmed Pharmaceuticals Ltd.'s principal executive offices are located at c/o Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, 5250608.

Does Galmed Pharmaceuticals Ltd. file annual reports under Form 20-F or 40-F?

Galmed Pharmaceuticals Ltd. indicates that it files annual reports under Form 20-F.

Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2025-10-29 16:05:17

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: October 29, 2025 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing